" class="no-js "lang="en-US"> Jerome Boyd-Kirkup - Medtech Alert
Tuesday, August 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Jerome Boyd-Kirkup

Jerome Boyd-Kirkup

About Jerome Boyd-Kirkup

Passionate Biochemical Researcher, Entrepreneur and Communicator
Co-founder and CSO of an award winning biotech
Extensive experience of integrating applied molecular biology and computational biology technologies
6+ years drug development experience in biotech
15+ years research experience in the UK and Asia
Two years experience in science communications for government and charities

Related Story

Diseases

 Hummingbird Bioscience and MD Anderson Announce Strategic Research Collaboration To Advance Innovative Immunotherapies | Pharmtech Focus

Hummingbird Bioscience and MD Anderson Announce Strategic Research Collaboration to Advance Innovative Immunotherapies

July 12 2021

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets […]